PerpEquities

Equity · Healthcare

Takeda Pharmaceutical Company Limited (TAKEDA) perpetual futures

TAKEDA perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade TAKEDAUSDT.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise that discovers, develops, manufactures, markets, and out-licenses medical products across Japan, the United States, Europe, and other regions.

$41.35-4.8%
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · MEXC (TAKEDA/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/1 live markets
Venues
1
Live markets
1/1
24h volume
$101.1K
Open interest
$362.5K
Best liquidity
$4.8K
MEXC
Tightest spread
+36.3 bps
MEXC
Highest volume
$101.1K
MEXC
Settlement mix
USDT · 1/1
Perp/spot vol.
0.00x
Spot volume $331.5M
OI / float
0.00%
Float $65.4B
Spot performance
1D-4.76%
5D-3.22%
1M+13.77%
6M+23.54%
YTD+33.44%
1Y+56.94%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeTAKEDA/USDTTrading$41.35+12.9% APR
+0.012% every 8h		+36.3 bps$4.8K$101.1K$362.5KUSDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 1 venues absorb $10k

Too thin: MEXC

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

TAKEDA
MEXC · TAKEDA/USDT$4.8K

Tightest spread

TAKEDA
MEXC · TAKEDA/USDT+36.3 bps

Highest volume

TAKEDA
MEXC · TAKEDA/USDT$101.1K

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q2 '26 · filed 2026-09-30 · next report 2027-01-28 · Updated 19h ago
All financials →

Valuation & key figures

Market cap
$66.2B
Updated 19h ago
Revenue
$29.6B
Trailing 12 months
Revenue growth
+4%
Next fiscal year
Profit margin
+8.2%
P/E
26.8
Peer P/E 36.2
P/S
2.2
Peer P/E
36.2
Similar listed perps
Free cash flow
$3.7B
Trailing 12 months
Net income
$2.4B
Trailing 12 months
Revenue estimate
$29.6B
Next fiscal year
Earnings
2027-01-28
Revenue est. $7.7B · Updated 19h ago
Dividend
¥102
2027-03-30
Revenue (TTM)¥4.69T+6.3% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)13.3%+3.3 pp vs a year agoOperating income ¥622B
Net income (TTM)¥385B+1,063.9% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)¥588B-36.9% vs a year agoCapex ¥186B
Diluted EPS (TTM)¥242.81+1,109.2% vs a year agoSum of the last 4 quarters
Net cash-¥4.12T-5.5% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-29): revenue beat by 2.8%, EPS beat by 166.9%Revenue ¥1.19T vs ¥1.16T expected (+2.8%); EPS ¥121.14 vs ¥45.38 (+166.9%).
  • Revenue growth accelerating: 6.7% year on yearQ2 '26 revenue ¥1.19T, against an average of 3.2% over the four quarters before.
  • Operating margin 13.3% (TTM), +3.3 pp on a year agoOperating income grew 40.9% while revenue grew 6.3%.
  • 55.5% of pre-tax profit is eaten by non-operating lossesPre-tax income ¥400B vs operating income ¥622B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates

Next catalyst

Catalysts

Earnings
2027-01-28
Revenue est. $7.7B · Updated 19h ago
Dividend
¥102
2027-03-30

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20270.96$29.6B+4%9
FY 20281.29$30.3B+7%13
FY 20291.59$31.3B+10%12
FY 20302.55$33.5B+18%5
FY 20312.15$33.4B+17%6
Q3 20260.29$7.3B-3%2

Company events

6
2027-03-30Dividend¥102-
2027-01-28EarningsActual - / Estimate 88.42-
2026-10-29EarningsActual 121.14 / Estimate 45.38Beat
2026-09-29Dividend¥102-
2026-07-30EarningsActual 71.65 / Estimate 53.12Beat
2026-05-13EarningsActual -15.58 / Estimate -24.04Beat

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
WUXIAPPTEC$66.7B7.716.0+45.5%1CAH$62.9B0.235.0+0.7%1BSX$62B2.918.0+16.6%3ARGX$58.3B12.942.8+29.6%1IDXX$53.3B11.445.6+25.4%1HUM$52.1B0.341.8+0.8%1HENGRUI$48.1B9.837.4+27.0%1NTRA$44.8B15.4-272.5-5.7%2

Company data

Company intelligence

Updated: Nov 2, 2026, 04:05 PM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chief executive
Julie So-Young Kim
Employees
47,029
IPO date
May 16, 1949
Country
JP
Exchange
Tokyo Stock Exchange
Website
Altman Z-scorei1.38
Piotroski scorei7/9
Overall ratingiB+
Owner earningsi¥246.22B¥157.57 per share

Rating factors

Return on equityi
3
Return on assetsi
3
Debt to equityi
1
Price to earningsi
2
Price to booki
4
Market cap history
¥10.39T+22.9%Aug 26 – Nov 26
¥8.45T¥9.42T¥10.39TLow: ¥8.45T · 2026-08-03Latest: ¥10.39T · 2026-11-02Aug 26Sep 26Oct 26Nov 26
Latest: ¥10.39T · 2026-11-02High: ¥10.39T · 2026-11-02Low: ¥8.45T · 2026-08-03
Largest fund holders
FundWeightShares held
1306.T0.89%54M
VXUS0.13%23.7M
VEA0.18%15.6M
IEFA0.27%12M
1321.T0.29%8.9M
EWJ1.31%7.3M
INJ0.91%6.8M
EFA0.32%5.7M
XWD.TO0.07%5.7M
IEE0.21%5.6M
BBJP1.25%5.5M
FSPSX0.27%5.5M

Analyst track record

How the analysts covering TAKEDA have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings00
Analysts00
Buy / hold / sell––
Upgrades / downgrades / initiations0 / 0 / 00 / 0 / 0
Price targets hit / missed––
Avg. return after a rating (TipRanks)––
Best / worst call– / –– / –

After buy calls on this stock: not enough measured cases yet

TipRanks data · computed Nov 4, 2026 · 0 ratings

Frequently asked questions

Where can I trade TAKEDA perpetual futures?

Takeda Pharmaceutical Company Limited (TAKEDA) perpetual futures trade on 1 crypto venues, including MEXC. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade TAKEDA around the clock?

Yes. Unlike the underlying stock, TAKEDA perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on TAKEDA perpetuals?

Right now the TAKEDA perp funding rate is +12.9% annualized (venue median), ranging from +12.9% to +12.9% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the TAKEDA perp price compare to the Takeda Pharmaceutical Company Limited stock?

The venue-median TAKEDA perp mark is $41.4 versus a reference stock price of $41.4, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a TAKEDA perpetual future?

A TAKEDA perpetual is a derivative that tracks the price of Takeda Pharmaceutical Company Limited with no expiry date. It lets you take long or short exposure to Takeda Pharmaceutical Company Limited on crypto venues, around the clock.

What is TAKEDAUSDT perpetual?

TAKEDAUSDT is the symbol most crypto exchanges use for the Takeda Pharmaceutical Company Limited perpetual settled in USDT (Tether). It tracks the TAKEDA share price through an index, trades 24/7 with leverage and never expires.

Other Healthcare perps

Also listed on MEXC

Embed this asset

TAKEDA perpetuals · perpequities.comTAKEDA perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/takeda-perp"><img src="https://perpequities.com/badge/takeda-perp.svg" width="240" height="64" alt="TAKEDA perpetuals · perpequities.com" loading="lazy"></a>

Raw data: JSON · CSV · API

Next step

Stay on top of TAKEDA perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for TAKEDA — one email every Sunday.

Watchlist and alerts

Price and funding alerts for TAKEDA, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X